Novel Thrombin Receptor Antagonist Doesn’t Increase Bleeding, Duke University Study

MedPage Today -- DURHAM, N.C., March 12 -- An investigational oral thrombin receptor antagonist didn’t increase bleeding in patients undergoing percutaneous coronary intervention (PCI), researchers here said.

MORE ON THIS TOPIC